Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Summary

Nurix Therapeutics announced the first patient enrollment in the Phase 3 DAYBreak CLL-306 trial of bexobrutideg versus pirtobrutinib for relapsed/refractory CLL/SLL previously treated with covalent BTK inhibitors. This registrational trial is designed to demonstrate the superiority of bexobrutideg over the comparator.